medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2011, Number 3

<< Back Next >>

Ann Hepatol 2011; 10 (3)

Hepatitis B virus infection has no significant role on lymphoproliferative disorders post liver transplantation: PTLD. int survey

Izadi M, Taheri S

Language: English
References: 36
Page: 315-320
PDF size: 53.39 Kb.


ABSTRACT

Introduction. Based on very limited data, it has been recently suggested that hepatitis B virus infection can play significant roles in post transplantation lymphoproliferative disorders. In the current study pooling data of PTLD in HBV positive liver recipients gathered from the existing literature, we sought to analyze and compare characteristics, behavior and prognosis of PTLD arising in HBV positive liver graft recipients. Methods. A comprehensive search for the available data though PubMed and Google Scholar for reports of PTLD and HBV infection in liver recipients was conducted. Data of 18 different studies were pooled and analyzed. Results. Liver recipients with HBV positive-PTLD were comparable to their HBV negative counterparts in gender, age at transplantation, time from transplantation to PTLD development, lymphoma cell type, histopathology of lesions, remission episodes, mortality rate, multi-organ involvement, and disseminated PTLD (p › 0.1 for all). HBV positive PTLD patients were significantly less likely to complicate spleen (0 vs. 23%, respectively; p = 0.015). Survival of the two patient groups were comparable (p = 0.8). Conclusion. HBV infection has no significant impact on inducing some distinct types of PTLD and represents no survival effect in PTLD setting. Future prospective studies are needed for confirming our findings.


REFERENCES

  1. Pourfarziani V, Ramezani MB, Taheri S, Izadi M, Einollahi B. Immunogenicity of pneumococcal vaccination in renal transplant recipients and hemodialysis patients: a comparative controlled trial. Ann Transplant 2008; 13(3): 43-7.

  2. Penn I, Hammond W, Brettschneider L, Starzl TE. Malignant lymphomas in transplantation patents. Transplant Proc 1969; 1(1): 106-12.

  3. Levy M, Backman L, Husberg B, et al. De novo malignancy following liver transplantation: a single-center study. Transplant Proc 1993; 25(1, Pt. 2): 1397-9.

  4. Nalesnik MA, Jaffe R, Starzl TE, et al. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol 1988; 133(1): 173-92.

  5. Stieber AO, Boillot O, Scotti-Foglieni C, et al. The surgical implications of the posttransplant lymphoproliferative disorders. Transplant Proc 1991; 23(1, Pt. 2): 1477-9.

  6. Malatack JF, Gartner JC Jr, Urbach AH, Zitelli BJ. Orthotopic liver transplantation, Epstein-Barr virus, cyclosporine, and lymphoproliferative disease: a growing concern. J Pediatr 1991; 118(5): 667-75.

  7. Renard TH, Andrews WS, Foster ME. Relationship between OKT3 administration, EBV seroconversion, and the lymphoproliferative syndrome in pediatric liver transplant recipients. Transplant Proc 1991; 23(1, Pt 2.): 1473-6.

  8. Cox KL, Lawrence-Miyasaki LS, Garcia-Kennedy R, et al. An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation. Transplantation 1995; 59(4): 524-9.

  9. Ulcickas YM, Quesenberry CP Jr, Guo D, et al. Incidence of non-Hodgkin’s lymphoma among individuals with chronic hepatitis B virus infection. Hepatology 2007: 46: 107.

  10. Wang F, Xu RH, Han B, et al. High incidence of hepatitis B virus infection in B-cell subtype non-Hodgkin lymphoma compared with other cancers. Cancer 2007: 109: 1360.

  11. Kim JH, Bang YJ, Park BJ, et al. Hepatitis B virus infection and B-cell non-Hodgkin’s lymphoma in a hepatitis B endemic area: a case-control study. Jpn J Cancer Res 2002: 93: 471.

  12. Luo Y, Zhang AB, Huang H, Zheng SS. Is hepatitis B virus reactivation a risk factor in the development of posttransplant lymphoproliferative disorder following liver transplantation? Chin Med J 2008; 121(13): 1237-40.

  13. Zhang A, Zhang M, Shen Y, Wang W, Zheng S. Hepatitis B virus reactivation is a risk factor for development of post-transplant lymphoproliferative disease after liver transplantation. Clin Transplant 2009; 23(5): 756-60. Epub 2009 Aug 2.

  14. McCormack L, Hany TI, Hübner M, Petrowsky H, Mullhaupt B, Knuth A, et al. How useful is PET/CT imaging in the management of post-transplant lymphoproliferative disease after liver transplantation? Am J Transplant 2006; 6(7): 1731-6.

  15. Aseni P, Vertemati M, De Carlis L, Sansalone CV, Bonacina E, Minola E, et al. De novo cancers and post-transplant lymphoproliferative disorder in adult liver transplantation. Pathol Int 2006; 56(11): 712-5.

  16. Nagarsheth NP, Kalir T, Rahaman J. Post-transplant lymphoproliferative disorder of the cervix. Gynecol Oncol 2005; 97(1): 271-5.

  17. Dhillon MS, Rai JK, Gunson BK, Olliff S, Olliff J. Post-transplant lymphoproliferative disease in liver transplantation. Br J Radiol 2007; 80(953): 337-46. Epub 2007 Mar 28.

  18. Burra P, Buda A, Livi U, Rigotti P, Zanus G, Calabrese F, et al. Occurrence of post-transplant lymphoproliferative disorders among over thousand adult recipients: any role for hepatitis C infection? Eur J Gastroenterol Hepatol 2006; 18(10): 1065-70.

  19. Cano B, Sanchez G, Montoliu G, Insa S, Masb F, Calderero V, et al. Imaging of liver-localized post-transplantion lymphoproliferative disease as complication of liver transplantion. Eur J Radiol Ext 2004; 49: 61-6.

  20. Baccarani U, Piselli P, Serraino D, Adani GL, Lorenzin D, Gambato M, et al. Comparison of de novo tumours after liver transplantation with incidence rates from Italian cancer registries. Dig Liver Dis 2010; 42(1): 55-60. Epub 2009 Jun 3.

  21. Lemoine A, Pham P, Azoulay D, Saliba F, Emile JF, Saffroy R, et al. Detection of gammopathy by serum protein electrophoresis for predicting and managing therapy of lymphoproliferative disorder in 911 recipients of liver transplants. Blood 2001; 98(5): 1332-8.

  22. Lorenzini S, Andreone P, Gramenzi A, et al. Posttransplant lymphoproliferative disorders in liver transplanted patients: a report of four cases. Transplant Proc 2006; 38: 1477-80.

  23. Nuckols JD, Baron PW, Stenzel TT, Olatidoye BA, Tuttle- Newhall JE, Clavien PA, Howell DN. The pathology of liverlocalized post-transplant lymphoproliferative disease: a report of three cases and a review of the literature. Am J Surg Pathol 2000; 24(5): 733-41. Review.

  24. De Diego JI, Prim MP, Hardisson D, Verdaguer JM, Jara P. Post-transplant lymphoproliferative disease in tonsils of children with liver transplantation. Int J Pediatr Otorhinolaryngol 2001; 58(2): 113-8.

  25. Zimmermann T, Hoppe-Lotichius M, Tripkovic V, Barreiros AP, Wehler TC, Zimmermann A, et al. Liver transplanted patients with preoperative autoimmune hepatitis and immunological disorders are at increased risk for Post- Transplant Lymphoproliferative Disease (PTLD). Eur J Intern Med 2010; 21(3): 208-15.

  26. Norin S, Kimby E, Ericzon BG, Christensson B, Sander B, Söderdahl G, Hägglund H. Posttransplant lymphoma-a single- center experience of 500 liver transplantations. Med Oncol 2004; 21(3): 273-84.

  27. Capello D, Cerri M, Muti G, Berra E, Oreste P, Deambrogi C, et al. Molecular histogenesis of posttransplantation lymphoproliferative disorders. Blood 2003; 102: 3775-85.

  28. Avolio AW, Agnes S, Barbarino R, Magalini SC, Frongillo F, Pagano L, et al. Posttransplant lymphoproliferative disorders after liver transplantation: analysis of early and late cases in a 255 patient series. Transplant Proc 2007; 39(6): 1956-60.

  29. Rohr JC, Wagner HJ, Lauten M, Wacker HH, Jüttner E, Hanke C, et al. Differentiation of EBV-induced post-transplant Hodgkin lymphoma from Hodgkin-like post-transplant lymphoproliferative disease. Pediatr Transplant 2008; 12(4): 426-31.

  30. Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993; 342: 1514-6.

  31. Izadi M, Taheri S. Features, predictors and prognosis of lymphoproliferative disorders post-liver transplantation regarding disease presentation time: Report from the PTLD.Int survey. Ann Transplant 2011; 16(1): 39-47.

  32. Khedmat H, Alavian SM, Taheri S. Significance of Epstein- Barr virus infection in the outcome of renal transplant patients with lymphoproliferative disorders. Ann Transplant 2010; 15(2): 40-4.

  33. Izadi M, Taheri S. Significance of in situ hybridization results for EBV-encoded RNA in post-transplantation lymphoproliferative disorder setting: Report from the PTLD.Int survey. Ann Transplant 2010; 15(4): 102-9.

  34. Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab [Letter]. N Engl J Med 2001; 344: 68-9.

  35. Ng HJ, Lim LC. Fulminant hepatitis B virus reactivation with concomitant listeriosis after fludarabine and rituximab therapy: case report. Ann Hematol 2001; 80: 549-52.

  36. Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti- CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17: 268-76.




2020     |     www.medigraphic.com